PEG-g-poly(GdDTPA-co-L-cystine): Effect of PEG chain length on in vivo contrast enhancement in MRI

Aaron M. Mohs, Yuda Zong, Junyu Guo, Dennis L. Parker, Zheng Rong Lu

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Biodegradable macromolecular Gd(III) complexes, Gd-DTPA cystine copolymers (GDCP), were grafted with PEG of different sizes to modify the physicochemical properties and in vivo MRI contrast enhancement of the agents and to study the effect of PEG chain length on these properties. Three new PEG-grafted biodegradable macromolecular gadolinium(III) complexes were synthesized and characterized as blood pool MRI contrast agents. One of three different lengths of MPEG-NH2 (MW = 550, 1000, and 2000) was grafted to the backbone of GDCP to yield PEGn-g-poly(GdDTPA-co-L-cystine), PEGn,-GDCP. The PEG chain length did not dramatically alter the T1 relaxivity, r1, of the modified agents. The MRI enhancement profile of PEGn-GDCP with different PEG sizes was significantly different in mice with respect to both signal intensity and clearance profiles. PEG2000-GDCP showed more prominent enhancement in the blood pool for a longer period of time than either PEG1000-GDCP or PEG550-GDCP. In the kidney, PEG2000-GDCP had less enhancement at 2 min than PEG1000-GDCP, but both PEG550-GDCP and PEG1000-GDCP showed a more pronounced signal decay thereafter. The three agents behaved similarly in the liver, as compared to that in the heart. All three agents showed little enhancement in the muscle. Chemical grafting with PEG of different chain lengths is an effective approach to modify the physiochemistry and in vivo contrast enhancement dynamics of the biodegradable macromolecular contrast agents. The novel agents are promising for further clinical development for cardiovascular and cancer MR imaging.

Original languageEnglish (US)
Pages (from-to)2305-2311
Number of pages7
JournalBiomacromolecules
Volume6
Issue number4
DOIs
StatePublished - Jul 1 2005

Fingerprint

Cystines
Cystine
Chain length
Magnetic resonance imaging
Polyethylene glycols
Copolymers
Contrast Media
gadolinium-DTPA cystine copolymer
Blood
Gadolinium
Liver
Muscle

ASJC Scopus subject areas

  • Organic Chemistry
  • Biochemistry, Genetics and Molecular Biology(all)
  • Polymers and Plastics
  • Materials Chemistry

Cite this

PEG-g-poly(GdDTPA-co-L-cystine) : Effect of PEG chain length on in vivo contrast enhancement in MRI. / Mohs, Aaron M.; Zong, Yuda; Guo, Junyu; Parker, Dennis L.; Lu, Zheng Rong.

In: Biomacromolecules, Vol. 6, No. 4, 01.07.2005, p. 2305-2311.

Research output: Contribution to journalArticle

Mohs, Aaron M. ; Zong, Yuda ; Guo, Junyu ; Parker, Dennis L. ; Lu, Zheng Rong. / PEG-g-poly(GdDTPA-co-L-cystine) : Effect of PEG chain length on in vivo contrast enhancement in MRI. In: Biomacromolecules. 2005 ; Vol. 6, No. 4. pp. 2305-2311.
@article{f8b69a09ed4c4d15aad1e2af2715dd26,
title = "PEG-g-poly(GdDTPA-co-L-cystine): Effect of PEG chain length on in vivo contrast enhancement in MRI",
abstract = "Biodegradable macromolecular Gd(III) complexes, Gd-DTPA cystine copolymers (GDCP), were grafted with PEG of different sizes to modify the physicochemical properties and in vivo MRI contrast enhancement of the agents and to study the effect of PEG chain length on these properties. Three new PEG-grafted biodegradable macromolecular gadolinium(III) complexes were synthesized and characterized as blood pool MRI contrast agents. One of three different lengths of MPEG-NH2 (MW = 550, 1000, and 2000) was grafted to the backbone of GDCP to yield PEGn-g-poly(GdDTPA-co-L-cystine), PEGn,-GDCP. The PEG chain length did not dramatically alter the T1 relaxivity, r1, of the modified agents. The MRI enhancement profile of PEGn-GDCP with different PEG sizes was significantly different in mice with respect to both signal intensity and clearance profiles. PEG2000-GDCP showed more prominent enhancement in the blood pool for a longer period of time than either PEG1000-GDCP or PEG550-GDCP. In the kidney, PEG2000-GDCP had less enhancement at 2 min than PEG1000-GDCP, but both PEG550-GDCP and PEG1000-GDCP showed a more pronounced signal decay thereafter. The three agents behaved similarly in the liver, as compared to that in the heart. All three agents showed little enhancement in the muscle. Chemical grafting with PEG of different chain lengths is an effective approach to modify the physiochemistry and in vivo contrast enhancement dynamics of the biodegradable macromolecular contrast agents. The novel agents are promising for further clinical development for cardiovascular and cancer MR imaging.",
author = "Mohs, {Aaron M.} and Yuda Zong and Junyu Guo and Parker, {Dennis L.} and Lu, {Zheng Rong}",
year = "2005",
month = "7",
day = "1",
doi = "10.1021/bm050194g",
language = "English (US)",
volume = "6",
pages = "2305--2311",
journal = "Biomacromolecules",
issn = "1525-7797",
publisher = "American Chemical Society",
number = "4",

}

TY - JOUR

T1 - PEG-g-poly(GdDTPA-co-L-cystine)

T2 - Effect of PEG chain length on in vivo contrast enhancement in MRI

AU - Mohs, Aaron M.

AU - Zong, Yuda

AU - Guo, Junyu

AU - Parker, Dennis L.

AU - Lu, Zheng Rong

PY - 2005/7/1

Y1 - 2005/7/1

N2 - Biodegradable macromolecular Gd(III) complexes, Gd-DTPA cystine copolymers (GDCP), were grafted with PEG of different sizes to modify the physicochemical properties and in vivo MRI contrast enhancement of the agents and to study the effect of PEG chain length on these properties. Three new PEG-grafted biodegradable macromolecular gadolinium(III) complexes were synthesized and characterized as blood pool MRI contrast agents. One of three different lengths of MPEG-NH2 (MW = 550, 1000, and 2000) was grafted to the backbone of GDCP to yield PEGn-g-poly(GdDTPA-co-L-cystine), PEGn,-GDCP. The PEG chain length did not dramatically alter the T1 relaxivity, r1, of the modified agents. The MRI enhancement profile of PEGn-GDCP with different PEG sizes was significantly different in mice with respect to both signal intensity and clearance profiles. PEG2000-GDCP showed more prominent enhancement in the blood pool for a longer period of time than either PEG1000-GDCP or PEG550-GDCP. In the kidney, PEG2000-GDCP had less enhancement at 2 min than PEG1000-GDCP, but both PEG550-GDCP and PEG1000-GDCP showed a more pronounced signal decay thereafter. The three agents behaved similarly in the liver, as compared to that in the heart. All three agents showed little enhancement in the muscle. Chemical grafting with PEG of different chain lengths is an effective approach to modify the physiochemistry and in vivo contrast enhancement dynamics of the biodegradable macromolecular contrast agents. The novel agents are promising for further clinical development for cardiovascular and cancer MR imaging.

AB - Biodegradable macromolecular Gd(III) complexes, Gd-DTPA cystine copolymers (GDCP), were grafted with PEG of different sizes to modify the physicochemical properties and in vivo MRI contrast enhancement of the agents and to study the effect of PEG chain length on these properties. Three new PEG-grafted biodegradable macromolecular gadolinium(III) complexes were synthesized and characterized as blood pool MRI contrast agents. One of three different lengths of MPEG-NH2 (MW = 550, 1000, and 2000) was grafted to the backbone of GDCP to yield PEGn-g-poly(GdDTPA-co-L-cystine), PEGn,-GDCP. The PEG chain length did not dramatically alter the T1 relaxivity, r1, of the modified agents. The MRI enhancement profile of PEGn-GDCP with different PEG sizes was significantly different in mice with respect to both signal intensity and clearance profiles. PEG2000-GDCP showed more prominent enhancement in the blood pool for a longer period of time than either PEG1000-GDCP or PEG550-GDCP. In the kidney, PEG2000-GDCP had less enhancement at 2 min than PEG1000-GDCP, but both PEG550-GDCP and PEG1000-GDCP showed a more pronounced signal decay thereafter. The three agents behaved similarly in the liver, as compared to that in the heart. All three agents showed little enhancement in the muscle. Chemical grafting with PEG of different chain lengths is an effective approach to modify the physiochemistry and in vivo contrast enhancement dynamics of the biodegradable macromolecular contrast agents. The novel agents are promising for further clinical development for cardiovascular and cancer MR imaging.

UR - http://www.scopus.com/inward/record.url?scp=22944434244&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22944434244&partnerID=8YFLogxK

U2 - 10.1021/bm050194g

DO - 10.1021/bm050194g

M3 - Article

C2 - 16004476

AN - SCOPUS:22944434244

VL - 6

SP - 2305

EP - 2311

JO - Biomacromolecules

JF - Biomacromolecules

SN - 1525-7797

IS - 4

ER -